Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer

Objective: To elucidate the potential role of HLA-G and classical HLA class I molecules in ovarian cancer, we researched their patterns of expression in benign and malignant ovarian tumors. Methods: In 10 benign and 33 malignant ovarian tumor tissues, HLA-G expression was determined both at the mRNA level by reverse transcriptase-polymerase chain reaction and immunohistochemical staining. The expression of classical HLA class I heavy chains were determined immunohistochemically. Results: Immunohistochemical analysis revealed the expression of HLA-G molecules in 27 of the 33 (81.8%) ovarian cancers but in none of the benign ovarian tumors. Classical HLA class I antigen expression was down-regulated in 25 out of the 33 (75.8%) ovarian cancers and in only 1 of the 10 benign ovarian tumors. HLA-G expression and classical HLA class I antigen down-regulation were related to disease stage (Spearman’s rho = 0.468, P = 0.001; Spearman’s rho = -0.392, P = 0.005). Conclusion: Our results reveal that abnormal expression of HLA-G and down-regulation of classical HLA class I antigen in ovarian cancer may be one of the mechanisms by which cancer cells may escape host’s immune system.

Ovarian cancer; Immune escape; Human leukocyte antigen class I molecule; Human leukocyte antigen-G

[1] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: A Cancer Journal for Clinicians. 2011; 61: 183-203.

[2] Ministry of Health & Welfare. Annual Report of the Korean Central Cancer Registry. Seoul. 2017.

[3] Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. The Journal of Reproductive Medicine. 2005; 50: 426-438.

[4] Ruiz-Cabello F, Klein E, Garrido F. MHC antigens on human tumors. Immunology Letters. 1991; 29: 181-189.

[5] Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy. 2010; 59: 529-540.

[6] Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clinical Cancer Research. 2005; 11: 2552-2560.

[7] Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Seminars in Cancer Biology. 2006; 16: 383-392.

[8] Yan WH. HLAG expression in cancers: potential role in diagnosis, prognosis and therapy. Endocrine Metabolic & Immune Disorders-Drug Targets. 2011; 11: 76-89.

[9] Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V. The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cellular and Molecular Life Sciences. 2011; 68: 341-352.

[10] Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, et al. Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. Journal of Cellular and Molecular Medicine. 2010; 14: 2318-2329.

[11] Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression, as a significant prognostic indicator for patients with colorectal cancer. Modern Pathology. 2007; 20: 375-383.

[12] Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, Zhang X, et al. Up-regulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Human Immunology. 2010; 71: 892-898.

[13] Yan WH. HLA-G expression in hematologic malignancies. Expert Review of Hematology. 2010; 3: 67-80.

[14] Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2’-deoxycytidine. Cell Research. 2005; 15: 523-531.

[15] Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. Journal of Clinical Investigation. 2002; 110: 1515-1523.

[16] Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLA-G is a potential tumor marker in malignant ascites. Clinical Cancer Research. 2003; 9: 4460-4464.

[17] Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Archives of Gynecology and Obstetrics. 2016; 293: 695-700.

[18] FIGO staging. Available at: https://www.figo.org/news/staging-ovftp-malignancies-0016123 (Accessed: 10 November 2018).

[19] Tumor cell grade fact sheet of national cancer institute (NCI). Available at: https://www.cancer.gov/about-cancer/diagnosis-s taging/prognosis/tumor-grade-fact-sheet.

[20] Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. Journal of Immunology. 2003; 171: 1918-1926.

[21] Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. Seminars in Cancer Biology. 2003; 13: 325-336.

[22] Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecologic Oncology. 2006; 103: 25-30.

[23] Amiot L, Onno M, Renard I, Drénou B, Guillaudeux T, Le Bouteiller P, et al. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens. 1996; 47: 408-413.

[24] Fournel S, Huc X, Aguerre-Girr M, Solier C, Legros M, Praud-Brethenou C, et al. Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens. 2000; 55: 510-518.

[25] Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of nonclassical class I genes transcription and protein expression. Human Immunology. 2000; 61: 1177-1195.

[26] Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Research. 2001; 61: 6838-6845.

[27] Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunology Today. 1997; 18: 89-95.

[28] Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clinical Cancer Research. 2005; 11: 67-72.

[29] Lee YS, Kim TE, Kim BK, Park YG, Kim GM, Jee SB, et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Experimental & Molecular Medicine. 2002; 34: 18-26.

[30] Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to firstline platinum chemotherapy. British Journal of Cancer. 2009; 101: 1321-1328.

[31] Zhu XM, Han T, Wang XH, Li YH, Yang HG, Luo YN, et al. Overexpression of miR-152 leads to reduced expression of human leukocyte Antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. American Journal of Obstetrics & Gynecology. 2010; 202: 592.e1-7.

[32] Paul P, Cabestré FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Re-search. 1999; 59: 1954-1960.

[33] Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, et al. Expression of HLA G in human tumors is not a frequent event. International Journal of Cancer. 1999; 81: 512-518.

[34] Pangault C, Amiot L, Caulet-Maugendre S, Brasseur F, Burtin F, Guilloux V, et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens. 1999; 53: 335-346.

[35] Le Rond S, Le Maoult J, Créput C, Menier C, Deschamps M, Le Friec G, et al. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. European Journal of Immunology. 2004; 34: 649-660.

[36] Sheikh MS, Fornace AJ Jr. Regulation of translation initiation following stress. Oncogene. 1999; 18: 6121-6128.

[37] Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Human Immunology. 2003; 64: 1057-1063.

[38] El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to hu-man development and disease. Gene Expression. 2000; 9: 63-75.

[39] Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 1191-1196.

[40] Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. American Journal of Pathology. 2001; 159: 817-824.